Methods for treating blood disorders

a technology for blood disorders and compounds, applied in the direction of drug compositions, peptide/protein ingredients, extracellular fluid disorders, etc., can solve the problems of increased cardiac output, impaired red blood cell production, red blood cell disorders and deficiencies,

Inactive Publication Date: 2008-03-27
COLORADO STATE UNIVERSITY +1
View PDF5 Cites 91 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I:

Problems solved by technology

In addition, infections by parasites such as Plasmodium, chemical injuries from, for example, lead poisoning, and sequestration in the mononuclear system such as by hyperspienism can result in red blood cell disorders and deficiencies.
Impaired red blood cell production can occur by disturbing the proliferation and differentiation of the stem cells or committed cells.
Symptoms of anemia include feelings of weakness or fatigue, pallor, shortness of breath, an increase in cardiac output, which may lead to palpitations and sweatiness.
In severe cases, anemia can lead to death by heart failure.
However, the prototype short chain fatty acids have limitations as therapeutics.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating blood disorders
  • Methods for treating blood disorders
  • Methods for treating blood disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of Small Molecule Inducers of Fetal Hemoglobin

[0209] Small molecule inducers of fetal hemoglobin were identified using computer modeling techniques.

[0210] The pharmacophore was constructed with the TFIT module of the FLO molecular modeling software. It was assumed that the carboxylic acids would bind to the receptor in an analogous fashion, and therefore, the superposition of the carboxylic oxygens was biased by imposing a 5 kJ superimposition energy constraint. Five hundred iterations of TFIT were used in the calculations.

[0211] TFIT produced an ensemble of low energy superimposition. The superimposition with the tightest overlay was taken to be the initial pharmacophore template. This pharmacophore was tested to see if it could distinguish between active and inactive compounds. TFIT was first used to determine the best match between the pharmacophore and four compounds which had been identified as inactive in the β / γ-globin promoter driven reporter gene assay in ...

example 2

IN Vitro Stimulation of Fetal Globin mRNA Expression

[0219] This example demonstrates that the test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in fetal (gamma) globin mRNA in cells cultured in vitro. Furthermore, the concentrations required were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions

[0220]γ-globin mRNA was analyzed in control and treated erythroid colonies cultured from cord blood, by RT-PCR.

[0221] Induction (increase) in fetal globin mRNA compared to untreated control levels with each compound is shown in Table 3 below. The R enantiomer of compound Y demonstrated fetal globin inducing action, whereas the S enantiomer did not induce fetal globin in 2 of (the same) 3 cultures.

TABLE 3Increase in Fetal Globin mRNAConcentrationMean changerequired,above co...

example 3

Effects on Erythroid and Myeloid Cell Growth In Vitro

[0224] This example demonstrates that the test compounds predicted to be active by reporter gene assays and molecular modeling produce a significant increase in numbers of erythroid and myeloid colonies or proportion of cells expressing fetal globin in in vitro cultured cells from a variety of sources under a variety of culture conditions. Similar to other in vitro tests described herein, the concentrations required for these biological effects were significantly lower (5-40 micromolar) than concentrations required for prior generation inducers (100-200 micromolar), making these compounds more suitable for therapeutic and pharmacologic compositions.

[0225] Compounds predicted in the molecular model to be γ-globin inducers were evaluated in a series of assays for activity in 1) stimulating activity from the fetal globin gene promoter, (the action which can ameliorate sickle cell disease and beta thalassemia), and 2) for any effect...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
superimposition energyaaaaaaaaaa
pHaaaaaaaaaa
enantiomersaaaaaaaaaa
Login to view more

Abstract

Methods of treating blood disorders are described.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60 / 799,054 filed May 9, 2006, which provisional application is incorporated herein by reference in its entirety.BACKGROUND [0002] 1. Field of the Invention [0003] The present invention relates to methods and compounds for the treatment of blood disorders. [0004] 2. Description of the Related Art [0005] The major function of red blood cells is to transport oxygen to tissues of the body, while minor functions include the transportation of nutrients and cytokines and the absorption of cellular metabolites. Anemia, defined as a loss of red blood cells or red blood cell capacity resulting in the reduction in the ability of the blood to transport oxygen, may be chronic or acute. Chronic anemia may be caused by extrinsic red blood cell abnormalities, intrinsic abnormalities or impaired production of red blood cells. Extrinsic or extra-corpusc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/20A61K31/10A61K31/19A61K31/34A61K31/35A61K31/36A61K31/38A61K31/41C07C63/64C07D317/44C07D277/04C07D215/12A61P7/00A61K31/415A61K31/425A61K31/44A61K31/47A61K31/517A61K31/54
CPCA61K31/192A61K31/194A61K31/36A61K31/39C07D311/12A61K31/517A61K31/353A61K31/433C07D285/125A61K31/415A61P43/00A61P7/00A61P7/06
Inventor PERRINE, SUSAN P.
Owner COLORADO STATE UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap